How big is the targeted DNA RNA sequencing market?

The global targeted DNA RNA sequencing market size was estimated at USD 7.40 billion in 2024 and is expected to reach USD 8.60 billion in 2025.

What is thetargeted DNA RNA sequencing market growth?

The global targeted DNA RNA sequencing market is expected to grow at a compound annual growth rate of 18.98% from 2025 to 2033 to reach USD 34.56 billion by 2033.

Which segment accounted for the largest targeted DNA RNA sequencing market share?

North America dominated the targeted DNA RNA sequencing market with a share of 43.03% in 2024. This is attributable to the presence of a large number of genome centers with installed sequencers.

Who are the key players in targeted DNA RNA sequencing market?

Some key players operating in the targeted DNA RNA sequencing market include Illumina, Inc.; F. Hoffmann-La Roche Ltd; Agilent Technologies; GATC Biotech Ag; Oxford Nanopore Technologies; Thermo Fisher Scientific, Inc.; DNASTAR Inc.; QIAGEN; BGI; Perkin Elmer, Inc.; Pacific Biosciences of California, Inc.; Bio-Rad Laboratories, Inc.; Integrated DNA Technologies, Inc.; RainDance Technologies, Inc.; PierianDx; Genomatix GmbH; and Macrogen, Inc.

What are the factors driving the targeted DNA RNA sequencing market?

Key factors that are driving the market growth include cost-saving advantages pertaining to the adoption of targeted sequencing approach as well as plummeting sequencing cost, advantages associated with targeted gene panels and amplicon sequencing, technological advancements in sequencing technology and related ancillary protocols, and rising number of targeted sequencing-based research projects and consequent popularity growth of genomic medicine